Atenolol-AFT Update

We currently have a stock shortage of Atenolol-AFT (atenolol 50 mg/10 mL) oral liquid 300 mL in both Australia and New Zealand. The only product currently held by AFT Pharmaceuticals expires in October 2018.

Due to problems at the manufacturing site we do not expect new stock to be available until February 2019. We are working with the manufacturer to expedite production of new stock.

We apologise for any inconvenience that is caused by this out of stock situation but it is due to circumstances outside of our control.

May 26, 2025

AFT and Hikma extend US Maxigesic Cooperation

AFT Pharmaceuticals (NZX:AFT, ASX:AFP) today announces it has extended its US Maxigesic® licensing agreement with Hikma Pharmaceuticals….

Read More

May 1, 2024

AFT Licenses Maxigesic® IV in Brazil

We are delighted to announce our partnership with Brazil’s Halex Istar, and to be exclusively responsible for distributing its Maxigesic IV in Brazi…

Read More

April 24, 2024

AFT, Massey Ventures, Gilles McIndoe to develop scar treatment

AFT collaborate with Massey Ventures and Gilles McIndoe to begin the development of a topical treatment for keloid and hypertrophic scarring….

Read More